Vipergen

Executive Summary

Vipergen is a privately held Danish biotechnology company headquartered in Copenhagen, founded in 2001. It is a world-leading provider of small molecule drug discovery services leveraging proprietary DNA-encoded library (DEL) technologies. The company differentiates itself by screening for novel compounds directly in living cells, accelerating lead generation for pharmaceutical partners. Despite limited public financial information, Vipergen's established presence in the DEL space and focus on cell-based screening positions it as a key partner for drug discovery programs. The company operates in a competitive landscape but benefits from its specialized expertise and long-standing track record.

Upcoming Catalysts (preview)

• TBDAnnouncement of a major pharmaceutical partnership for cell-based DEL screening65% success
• TBDExpansion of DEL platform to new therapeutic areas (e.g., oncology or CNS)50% success
• TBDPublication of preclinical validation data from proprietary DEL campaigns70% success